Ralph A. de Groot

Ralph A. de Groot

Auto-generated profile, based on publicly available information

Ralph A. de Groot

Utrecht Institute for Pharmaceutical Sciences

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
JRJe-Kyung Ryu
Je-Kyung Ryu
CBCéline Bouchoux
Céline Bouchoux
HLHon Wing Liu
Hon Wing Liu
EKEugene Kim
Eugene Kim
MMMasashi Minamino
Masashi Minamino
CDCees Dekker
Cees Dekker
Yeast cohesin complexes cluster onto long DNA into liquid droplets, which they accomplish by ATP-independent DNA bridging.

1 September 2025 in American Journal of Physiology-Cell Physiology
Verified
Journal Article
Closed access
RGRalph A. de Groot
Ralph A. de Groot
DRDaan Reedijk
Daan Reedijk
QFQuentin Faucher
Quentin Faucher
SMSilvia Mihaila
Silvia Mihaila
RMRosalinde Masereeuw
Rosalinde Masereeuw
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with multidrug resistance (MDR) significantly limiting the effectiveness of chemotherapy. A major contributor to MDR is the overexpression of ATP-binding cassette (ABC) transporters, such as P-glycoprotein ( ABCB1/P-gp), breast cancer resistance protein ( ABCG2/BCRP), and multidrug resistance-associated proteins ( ABCC/MRPs). These transporters actively efflux chemotherapeutic agents, reducing their intracellular drug accumulation and efficacy. This review outlines both clinical and emerging strategies that aim to overcome ABC transporter-mediated resistance in CRC. Herein, we detail the functional role of ABC transporters in CRC, followed by clinically tested approaches, such as pharmacological inhibitors, natural compound inhibitors, as well as nanoparticle-based drug delivery systems, that have been explored to circumvent resistance. In addition, we discuss emerging preclinical approaches, including CRISPR/Cas9 gene-editing, RNA interference, epigenetic modulators, and gut microbiome-targeted interventions, that hold promise for future therapeutic translation. By integrating clinically validated and experimental strategies, this review highlights the importance of a multimodal approach to effectively circumvent MDR in CRC and optimize personalized treatment strategies to improve clinical outcomes. ABC transporters; chemoresistance; colorectal cancer; multidrug resistance; therapies